Omeros | OMER - Assets


Omeros reported $200.57M in Assets for its fiscal quarter ending in June of 2025.





Assets Change Date
Adma Biologics USD 624.24M 55.56M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Cytokinetics USD 1.42B 12.02M Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
Heron Therapeutics USD 255.88M 6.93M Dec/2025
Immunic USD 40.7M 20.72M Sep/2025
Insmed USD 2.26B 96.18M Dec/2025
Knight Therapeutics CAD 1.05B 2.28M Dec/2025
MacroGenics USD 256.85M 13.92M Dec/2025
Omeros USD 200.57M 34.59M Jun/2025
Pacira USD 1.26B 32.66M Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
Rockwell Medical USD 52.62M 1.34M Jun/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
United Therapeutics USD 7.88B 528.9M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025
Xoma USD 263.15M 39.7M Sep/2025